146 related articles for article (PubMed ID: 31173243)
1. Silibinin A decreases statin‑induced PCSK9 expression in human hepatoblastoma HepG2 cells.
Dong Z; Zhang W; Chen S; Liu C
Mol Med Rep; 2019 Aug; 20(2):1383-1392. PubMed ID: 31173243
[TBL] [Abstract][Full Text] [Related]
2. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
3. Butein Synergizes with Statin to Upregulate Low-Density Lipoprotein Receptor Through
Hwang JT; Kim HJ; Choi HK; Park JH; Chung S; Chung MY
J Med Food; 2020 Oct; 23(10):1102-1108. PubMed ID: 32835593
[TBL] [Abstract][Full Text] [Related]
4. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
[TBL] [Abstract][Full Text] [Related]
5. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
[TBL] [Abstract][Full Text] [Related]
6. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Yang X; Zhang J; Chen L; Wu Q; Yu C
Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
[TBL] [Abstract][Full Text] [Related]
7. Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters.
Dong B; Singh AB; Shende VR; Liu J
Int J Mol Med; 2017 Mar; 39(3):749-756. PubMed ID: 28204827
[TBL] [Abstract][Full Text] [Related]
8. The Cholesterol-Modulating Effect of Methanol Extract of Pigeon Pea (
Chang HY; Wu JR; Gao WY; Lin HR; Chen PY; Chen CI; Wu MJ; Yen JH
Molecules; 2019 Jan; 24(3):. PubMed ID: 30704067
[TBL] [Abstract][Full Text] [Related]
9. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
10. Black Raspberry Extract Enhances LDL Uptake in HepG2 Cells by Suppressing PCSK9 Expression to Upregulate LDLR Expression.
Song KH; Kim YH; Im AR; Kim YH
J Med Food; 2018 Jun; 21(6):560-567. PubMed ID: 29569973
[TBL] [Abstract][Full Text] [Related]
11. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Nozue T
J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
[TBL] [Abstract][Full Text] [Related]
12. Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9
Lammi C; Bollati C; Lecca D; Abbracchio MP; Arnoldi A
Nutrients; 2019 Jul; 11(7):. PubMed ID: 31330826
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
Dong B; Wu M; Cao A; Li H; Liu J
Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
[TBL] [Abstract][Full Text] [Related]
14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
Lan H; Pang L; Smith MM; Levitan D; Ding W; Liu L; Shan L; Shah VV; Laverty M; Arreaza G; Zhang Q; Murgolo NJ; Hernandez M; Greene JR; Gustafson EL; Bayne ML; Davis HR; Hedrick JA
J Cell Physiol; 2010 Jul; 224(1):273-81. PubMed ID: 20333646
[TBL] [Abstract][Full Text] [Related]
16. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
17. A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro.
Li L; Shen C; Huang YX; Li YN; Liu XF; Liu XM; Liu JH
Molecules; 2018 Sep; 23(9):. PubMed ID: 30235833
[TBL] [Abstract][Full Text] [Related]
18. Regulatory mechanism of mineral-balanced deep sea water on hypocholesterolemic effects in HepG2 hepatic cells.
Lee KS; Kwon YS; Kim S; Moon DS; Kim HJ; Nam KS
Biomed Pharmacother; 2017 Feb; 86():405-413. PubMed ID: 28012395
[TBL] [Abstract][Full Text] [Related]
19. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
[TBL] [Abstract][Full Text] [Related]
20. Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
Taylor BA; Thompson PD
Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]